Clinical Trial Update: Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring camrelizumab with SBRT and concurrent chemotherapy for stage IV oligometastatic non-small cell lung cancer, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: UNKNOWN